Clear Street analyst Kaveri Pohlman initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $29 price target. Once-daily oral denifanstat had “exceptional” Phase 2b F2-F3 data, “outstanding” Phase 3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals’ (MDGL) Rezdiffra, the analyst tells investors. The firm sees Sagimet as “a compelling growth story,” stating that using “conservative valuation metrics,” the firm’s target implies substantial upside when compared to Boston Pharma’s recent $1.2B upfront acquisition value.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences to present Phase 2b FASCINATE-2 study results
- Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential
- Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom
- Sagimet Biosciences reports data from Phase 3 trial on denifanstat
- Sagimet Biosciences announces presentations at MASH Drug Development Summit